SEATTLE, April 30 -- The epilepsy drug levetiracetam (Keppra) does not appear to be effective for prevention of chronic daily headache, researchers said here.
Action Points Explain that the epilepsy drug levetiracetam did not significantly increase the headache-free rate for patients with chronic daily headache compared with placebo.Note, however, that there was a significant reduction in disability and reduced pain severity in the treatment group, and the findings show that there is a subpopulation of chronic daily headache patients for whom levetiracetam remains a therapeutic option.Note that this study was published as an abstract and presented orally at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.
Levetiracetam drug achieved a 3.9% increase in headache-free performance over placebo, but the trend did not reach statistical significance, Roy Beran, M.D., of the University of New South Wales, and colleagues reported at the American Academy of Neurology meeting.
Matti Narkia on 15 Apr 09TUESDAY, April 14 (HealthDay News) -- A particular type of stem cell transplantation using the patient's own cells led to short-term freedom from insulin injections in 20 of 23 patients newly diagnosed with type 1 diabetes participating in an experimental protocol in Brazil. One patient even managed to go four years without needing outside sources of insulin, although the average was 31 months, said the authors of a report in the April 15 issue of the Journal of the American Medical Association, a themed issue on diabetes. The patients also kept their blood sugar under control, which is key to preventing complications from diabetes. And, the authors stated, increased C-peptide levels indicated that the pancreas' beta cells were alive and well.
